EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
3.4.16.2 | diisopropyl fluorophosphate | 1 mM, complete inhibition | Homo sapiens | |
3.4.16.2 | pepstatin | 0.3 mM, complete inhibition | Homo sapiens | |
3.4.16.2 | phenylmethylsulfonyl fluoride | 1 mM, complete inhibition | Homo sapiens |
EC Number | KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|---|
3.4.16.2 | 0.77 | - |
N-benzyloxycarbonyl-Pro-Phe | - |
Homo sapiens | |
3.4.16.2 | 1 | - |
angiotensin II | - |
Homo sapiens | |
3.4.16.2 | 2 | - |
angiotensin III | - |
Homo sapiens |
EC Number | Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
---|---|---|---|---|
3.4.16.2 | 45000 | - |
x * 45000 + x * 66500, SDS-PAGE in presence of 2-mercaptoethanol | Homo sapiens |
3.4.16.2 | 66500 | - |
x * 45000 + x * 66500, SDS-PAGE in presence of 2-mercaptoethanol | Homo sapiens |
3.4.16.2 | 115000 | - |
gel filtration | Homo sapiens |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
3.4.16.2 | Homo sapiens | - |
- |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
3.4.16.2 | blood | - |
Homo sapiens | - |
3.4.16.2 | fibroblast | - |
Homo sapiens | - |
3.4.16.2 | kidney | - |
Homo sapiens | - |
3.4.16.2 | lung | - |
Homo sapiens | - |
3.4.16.2 | lymphocyte | - |
Homo sapiens | - |
3.4.16.2 | macrophage | - |
Homo sapiens | - |
3.4.16.2 | polymorphonuclear leukocyte | - |
Homo sapiens | - |
3.4.16.2 | urine | - |
Homo sapiens | - |
EC Number | Specific Activity Minimum [µmol/min/mg] | Specific Activity Maximum [µmol/min/mg] | Comment | Organism |
---|---|---|---|---|
3.4.16.2 | 0.51 | - |
- |
Homo sapiens |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.4.16.2 | angiotensin II + H2O | about 35% of the activity with angiotensin III | Homo sapiens | ? | - |
? | |
3.4.16.2 | angiotensin III + H2O | - |
Homo sapiens | ? | - |
? | |
3.4.16.2 | N-benzyloxycarbonyl-Pro-Ala + H2O | 33% of the activity with angiotensin III | Homo sapiens | N-benzyloxycarbonyl-Pro + Ala | - |
? | |
3.4.16.2 | N-benzyloxycarbonyl-Pro-Leu + H2O | 12% of the activity with angiotensin III | Homo sapiens | N-benzyloxycarbonyl-Pro + Leu | - |
? | |
3.4.16.2 | N-benzyloxycarbonyl-Pro-Phe + H2O | 8% of the activity with angiotensin III | Homo sapiens | N-benzyloxycarbonyl-Pro + Phe | - |
? | |
3.4.16.2 | N-benzyloxycarbonyl-Pro-Ser + H2O | 7% of the activity with angiotensin III | Homo sapiens | N-benzyloxycarbonyl-Pro + Ser | - |
? | |
3.4.16.2 | N-benzyloxycarbonyl-Pro-Val + H2O | 28% of the activity with angiotensin III | Homo sapiens | N-benzyloxycarbonyl-Pro + Val | - |
? |
EC Number | Subunits | Comment | Organism |
---|---|---|---|
3.4.16.2 | ? | x * 45000 + x * 66500, SDS-PAGE in presence of 2-mercaptoethanol | Homo sapiens |
EC Number | Temperature Stability Minimum [°C] | Temperature Stability Maximum [°C] | Comment | Organism |
---|---|---|---|---|
3.4.16.2 | 60 | - |
30 min, 20% loss of activity | Homo sapiens |
3.4.16.2 | 70 | - |
15 min, 90% loss of activity | Homo sapiens |
EC Number | pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|---|
3.4.16.2 | 4.5 | 5.5 | with N-benzyloxycarbonyl-Pro-Phe, angiotensin II or angiotensin III as substrate | Homo sapiens |
EC Number | pH Minimum | pH Maximum | Comment | Organism |
---|---|---|---|---|
3.4.16.2 | 4.5 | 7 | - |
Homo sapiens |